HEPARIN SODIUM INJECTION USP SOLUTION

Pajjiż: Kanada

Lingwa: Ingliż

Sors: Health Canada

Ingredjent attiv:

HEPARIN SODIUM

Disponibbli minn:

PFIZER CANADA ULC

Kodiċi ATC:

B01AB01

INN (Isem Internazzjonali):

HEPARIN

Dożaġġ:

10000UNIT

Għamla farmaċewtika:

SOLUTION

Kompożizzjoni:

HEPARIN SODIUM 10000UNIT

Rotta amministrattiva:

INTRAVENOUS

Unitajiet fil-pakkett:

1ML/25X1ML

Tip ta 'preskrizzjoni:

Ethical

Żona terapewtika:

HEPARINS

Sommarju tal-prodott:

Active ingredient group (AIG) number: 0104596002; AHFS:

L-istatus ta 'awtorizzazzjoni:

MARKETED

Data ta 'l-awtorizzazzjoni:

2013-03-01

Karatteristiċi tal-prodott

PRODUCT MONOGRAPH
HEPARIN SODIUM INJECTION USP
FOR INTRAVENOUS OR SUBCUTANEOUS USE
10 000 USP UNITS PER ML
ANTICOAGULANT
Pfizer Canada ULC
DATE OF INITIAL APPROVAL:
17300 Trans Canada Highway
November 1, 2012
Kirkland, Quebec
H9J 2M5
DATE OF REVISION:
January 9, 2020
CONTROL NO.: 228415
_ _
_ _
Heparin Sodium Injection_ _USP _ _
Page 2 of 28_ _
Pfizer Canada ULC
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
..........................................................3
SUMMARY PRODUCT INFORMATION
.....................................................................3
INDICATIONS AND CLINICAL USE
...........................................................................3
CONTRAINDICATIONS
.................................................................................................4
WARNINGS AND PRECAUTIONS
...............................................................................4
ADVERSE REACTIONS
..................................................................................................9
DRUG INTERACTIONS
................................................................................................12
DOSAGE AND ADMINISTRATION
...........................................................................14
OVERDOSAGE
...............................................................................................................18
ACTIONS AND CLINICAL PHARMACOLOGY
......................................................18
STORAGE AND
STABILITY........................................................................................19
DOSAGE FORMS, COMPOSITION AND PACKAGING
........................................20
PART II: SCIENTIFIC INFORMATION
................................................................................21
PHARMACEUTICAL INFORMATION
......................................................................21
CLINICAL TRIALS
........................................................................................................22
REFERENCES
......................................